Theravance Biopharma, Inc. cotiza a 17.03 USD y tiene una capitalización bursátil de $884M. En los últimos 12 meses ha facturado $104M con un margen de flujo de caja libre del 221.9%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinep…
| Periodo | 2026-11 |
|---|---|
| Real | — |
| Estimado | $0.20 |
| Sorpresa | — |
| Métrica | TBPH | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -3.4% | -38.6% | +35.3% |
| Net Margin | 98.5% | -33.6% | +132.1% |
| FCF Margin | 221.9% | -13.9% | +235.8% |
| ROE | 35.7% | -40.4% | +76.1% |
| ROA | 21.8% | -32.0% | +53.8% |
| Current Ratio | 10.93 | 2.84 | +8.09 |
| Debt / Equity | — | 0.28 | — |